Tyrosine News and Research

RSS

Gene identified that confers susceptibility to age-related macular degeneration

By combining the tools of high-throughput biology and statistical genetics, scientists at Rockefeller University, Yale University School of Public Health and the National Eye Institute have identified a gene that confers susceptibility to age-related macular degeneration (AMD), the most common cause of vision loss in the United Sates for those over 60.

14 Mar 2005

New compound, AMN107, 20 times more potent than Gleevec for chronic myelogenous leukemia treatment

A laboratory study led by researchers at Dana-Farber Cancer Institute has shown that a potent and highly selective therapy for chronic myelogenous leukemia (CML) may ultimately be more effective than Gleevec®, the current standard of care.

21 Feb 2005

New compound AMN107 may help treat some imatinib resistant cancer cases

As scientists uncover the precise molecular mechanisms that underlie effective cancer treatments, they gain invaluable insight into why predominantly successful treatments fail for some patients.

14 Feb 2005

Researchers shed new light on the development of cancers, particularly breast and prostate cancer

Researchers at Brown Medical School and Rhode Island Hospital have shed new light on the activation of a protein key to the development of cancers, particularly breast and prostate cancer, the most commonly diagnosed cancers in the United States.

13 Jan 2005

Common ingredient in some shampoos (methylisothiazolinone) stunts developing neurons of rats

An antimicrobial agent found in some shampoos and hand creams and widely used in industrial settings inhibits the development of particular neuron structures that are essential for transmitting signals between cells.

6 Dec 2004

Enzyme that normally alters the activity of other protein molecules in cells may also help prevent cancer

The enzyme is known as PTPRO (for “protein tyrosine phosphatase receptor-type O”). When the gene responsible for producing PTPRO is silenced, as can happen in lung cancer, for example, the amount of the enzyme drops, allowing the cells to grow when they shouldn’t.

11 Nov 2004

Shp2 protein plays a critical role in obesity

A team of researchers led by The Burnham Institute's Gen-Sheng Feng, Ph.D. has discovered that a protein called Shp2 plays a critical role in obesity.

11 Nov 2004

First home-testing device for phenylketonuria (PKU) patients

Home-testing kits have made it easier for diabetics and hypertension patients to track their conditions, but such self-monitoring hasn’t been possible for people with phenylketonuria (PKU).

1 Nov 2004

Evidence links cellular iron deficiency to restless legs syndrome

Iron-deficient cells in the brain are mixing up central nervous system signals to the legs and arms causing the irresistible urges to move and creepy-crawly sensations that characterize restless legs syndrome (RLS), a Penn State College of Medicine study reports.

25 Oct 2004

Newly discovered gene could be a significant contributor to diabetes in Americans

A gene involved in the action of insulin is associated with type 2 diabetes and the body’s response to insulin, report scientists at Wake Forest University Baptist Medical Center.

25 Oct 2004

Scientists have developed a new technology capable of improving survival outcomes after bone marrow transplantation

The study was published in the September issue of the prestigious medical journal, British Journal of Hematology. The technology involves the rational design and application of tyrosine kinase inhibitors for the treatment of leukemia, lymphoma, and graft versus host disease.

8 Oct 2004

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

21 Sep 2004

HER-2 cell surface receptors tun on genes associated with carcinogenesis

Researchers at The University of Texas M. D. Anderson Cancer Center now have evidence that receptors found on tumors that were believed to function only on the surface of cells can actually switch on genes inside a cell's nucleus, thus promoting cancer development in two distinct ways.

21 Sep 2004

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.

20 Sep 2004

New compound that is designed to overcome Gleevec resistance

One of the truly spectacular success stories in modern oncology is the development and implementation of Gleevec, a drug that virtually halts the progress of chronic myeloid leukemia. Yet for some patients who harbor particularly stubborn genetic mutations, Gleevec fails miserably.

17 Jul 2004

New compound, ZK-CDK combines the inhibition of tumour cell growth as well as inhibition of tumour angiogenesis in one single molecule

Treatment with a new dual cell cycle and angiogenesis pathway inhibitor blocks VEGF-induced vascular permeability, inhibits tumour angiogenesis and induces apoptosis in human tumour models

7 Jul 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Cancer drug gefitinib (Iressa) may be able to restore tamoxifen's anticancer activity

A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug--gefitinib (Iressa)--may be able to restore tamoxifen's anticancer activity.

15 Jun 2004

Multi-targeted anticancer drug shows promise as treatment for metastatic renal cell cancer

A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers.

6 Jun 2004

Drug Tarceva improves survival chance for patients with advanced lung cancer

Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).

5 Jun 2004